Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Challenge Dose of GSK Biologicals' Hepatitis B Virus Vaccine, Engerix™-B Kinder (SKF103860), in 15-16 Years Old Adolescents, Vaccinated in Infancy With Engerix™-B Kinder

NCT01847430 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01847430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01847430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Challenge Dose of GSK Biologicals' Hepatitis B Virus Vaccine, Engerix™-B Kinder (SKF103860), in 15-16 Years Old Adolescents, Vaccinated in Infancy With Engerix™-B Kinder
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
July 19, 2013
Completion date
February 21, 2014
Enrollment
303 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b